title: Renal production of thromboxane and prostaglandins in a rat model of type 2 diabetes.
abstract: In an investigation of the involvement of prostanoids in the pathogenesis of nephropathy in type 2 diabetes, we repeatedly measured the urinary excretion of prostanoids in both diabetic and healthy rats as the rats aged. Seven rats of the Otsuka Long-Evans Tokushima Fatty strain were used as rats with a model of type 2 diabetes and seven rats of the Long-Evans Tokushima Otsuka strain were used as rats without diabetes. Thromboxane (TX) B2 and 6-keto-prostaglandin (PG) F1alpha, the amounts of which reflect renal production of TXA2 and PGI2, respectively, and PGE2 in urine collected in metabolic cages were assayed when rats were 14, 30, 46, and 54 weeks old. Plasma glucose and urinary protein excretion also were measured periodically. The mean plasma glucose concentration of the diabetic rats was higher than that of the healthy rats throughout the study. At 30 weeks and later, urinary protein excretion by the diabetic rats was greater than that of the healthy rats, and it increased with age. Urinary excretion of TXB2 by the diabetic rats was higher than that of the healthy rats at 14 weeks (52.4+/-23.5 vs. 27.0+/-2.6 ng/day; mean +/- SD, P = .015) and the difference continued to the end of the experiment. Urinary excretion of 6-keto-PGF1alpha by the diabetic rats was high at 14 weeks (52.3+/-12.8 vs. 26.9+/-4.6 ng/day; mean +/- SD, P<.001) but decreased with age and was the same as that of the healthy rats at 54 weeks. The urinary excretion of PGE2 by the two groups of rats was not significantly different. These results suggest that altered renal production of TXA2 and PGI2 is involved in the pathogenesis of diabetic nephropathy in rats with type 2 diabetes.
authors.affiliation: Department of Internal Medicine, Osaka City General Hospital, Osaka, Japan. m5178790@msic.med.osaka-cu.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Okumura
authors.forename: M
authors.initials: M
authors.lastname: Imanishi
authors.forename: T
authors.initials: T
authors.lastname: Yamashita
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamura
authors.forename: S
authors.initials: S
authors.lastname: Kim
authors.forename: H
authors.initials: H
authors.lastname: Iwao
authors.forename: S
authors.initials: S
authors.lastname: Tanaka
authors.forename: S
authors.initials: S
authors.lastname: Fujii
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D000375:Aging; D000818:Animals; D001786:Blood Glucose; D001835:Body Weight; D003404:Creatinine / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000378:metabolism* / Q000503:physiopathology / Q000652:urine; D015232:Dinoprostone / Q000652:urine; D004195:Disease Models, Animal; D007668:Kidney / Q000378:metabolism* / Q000503:physiopathology; D008297:Male; D011453:Prostaglandins / Q000652:urine*; D051381:Rats; D020334:Rats, Inbred OLETF; D020318:Rats, Long-Evans; D013929:Thromboxane B2 / Q000652:urine; D013931:Thromboxanes / Q000652:urine*
chemical_list: D001786:Blood Glucose; D011453:Prostaglandins; D013931:Thromboxanes; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D003404:Creatinine; D015232:Dinoprostone